North Carolina Cannabis Laws: Medical, Hemp & Legalization Status

Executive Summary

North Carolina maintains one of the most restrictive cannabis frameworks in the Southeast, with no legal pathway for adult-use or comprehensive medical marijuana as of May 2026. Possession of any amount remains a criminal misdemeanor under N.C. Gen. Stat. § 90-95(a)(3), punishable by up to 30 days in jail and a $200 fine for first offenses. The state decriminalized low-THC CBD oil for intractable epilepsy in 2014 and expanded access to terminally ill patients in 2015, but these narrow exceptions leave North Carolina as one of 14 states without a full medical cannabis program. Recent legislative efforts, including a 2023 Senate-passed medical marijuana bill that stalled in the House, have exposed deep partisan and cultural divides. Meanwhile, a booming hemp-derived delta-8 THC market operates in a regulatory gray zone, prompting renewed calls from Republican health leaders in May 2026 to overhaul the state's patchwork cannabis, hemp, and tobacco laws. The outcome will determine whether North Carolina joins neighboring Virginia and South Carolina in expanding patient access or remains an enforcement-focused outlier.

Why This Matters

North Carolina's cannabis policy affects 10.7 million residents, thousands of patients with qualifying conditions, a $1.2 billion potential medical market, and the state's position in the regional hemp economy. The state's prohibition forces patients to seek relief in neighboring states or turn to unregulated hemp-derived products, creating public health risks and enforcement inconsistencies. Law enforcement agencies report that cannabis possession arrests consume significant resources, with over 14,000 misdemeanor marijuana charges filed annually according to North Carolina Administrative Office of the Courts data. For operators, North Carolina represents untapped opportunity. A 2022 East Carolina University study estimated a regulated medical cannabis program could generate $50-80 million in annual state tax revenue and create 8,000-12,000 jobs. Multi-state operators including Trulieve, Curaleaf, and Green Thumb Industries have signaled interest in entering the market pending legalization, with site acquisition already underway in Charlotte, Raleigh, and Asheville metro areas. Patient advocacy groups including North Carolina Families for Medical Cannabis report membership exceeding 15,000, with veterans, cancer patients, and epilepsy families comprising the core constituencies. The prohibition particularly impacts rural communities where opioid addiction rates exceed state averages, and where medical cannabis could offer an alternative pain management pathway. The May 2026 GOP health committee proposals targeting cannabis, hemp, and tobacco signal a potential inflection point, with implications extending beyond North Carolina to influence policy debates in Tennessee, Georgia, and other prohibition states watching closely.

Background and History: From Total Prohibition to Incremental Reform

North Carolina criminalized cannabis in 1923 as part of the national wave of state-level prohibition, and the framework has remained largely unchanged for a century.

Early Prohibition Era (1923-1970)

The North Carolina General Assembly enacted its first cannabis prohibition statute in 1923, classifying marijuana as a narcotic alongside opium and cocaine. The law imposed criminal penalties for possession, sale, and cultivation, with no distinction between medical and recreational use. This framework remained static through the federal Marihuana Tax Act of 1937 and the post-war decades, with enforcement focused primarily on communities of color in urban centers including Durham, Charlotte, and Wilmington.

Federal Controlled Substances Act Alignment (1971)

Following passage of the federal Controlled Substances Act in 1970, North Carolina updated its statutes in 1971 to align with the DEA's five-schedule framework. Cannabis was placed in Schedule VI under N.C. Gen. Stat. § 90-94, the state's unique classification for marijuana and synthetic cannabinoids. This schedule carries lighter penalties than Schedule I-V substances but maintains criminal sanctions. The 1971 law established the possession penalty structure still in effect: up to 30 days and $200 for first offense, up to 45 days and $1,000 for subsequent offenses.

Medical Research Allowance (1982)

In 1982, the General Assembly passed the Controlled Substances Therapeutic Research Act, allowing state universities to conduct FDA-approved research on cannabis for cancer and glaucoma patients. No research programs materialized due to federal restrictions on obtaining research-grade cannabis from the National Institute on Drug Abuse. The law remained symbolic until its repeal in 2015.

Hemp Pilot Program (2015)

The 2014 federal Farm Bill authorized state hemp pilot programs for research purposes. North Carolina responded with the Industrial Hemp Research Program in 2015, administered by the North Carolina Department of Agriculture and Consumer Services. The program licensed 1,200 acres for cultivation by 2017, focusing on fiber and seed production. This marked the first legal cannabis cultivation in the state since 1923, though limited to hemp with less than 0.3% delta-9 THC.

CBD Oil for Epilepsy (2014-2015)

Advocacy by families of children with Dravet syndrome and Lennox-Gastaut syndrome led to passage of the Epilepsy Alternative Treatment Act in 2014. The law created an affirmative defense for possession of CBD oil containing less than 0.9% THC and at least 5% CBD for patients with intractable epilepsy. In 2015, the Hope for Haley and Friends Act expanded the affirmative defense to include hemp-extract with less than 0.3% THC for the same patient population. Neither law established a legal in-state supply chain, forcing families to obtain products from other states or online retailers.

Terminally Ill Patient Access (2015)

Senate Bill 648, enacted in 2015, created the North Carolina Medical Cannabis Act for terminally ill patients. The law allows physicians to certify patients with terminal diagnoses and less than 12 months to live to possess and use cannabis without criminal penalty. The statute provides no legal source for obtaining cannabis, rendering it largely symbolic. As of 2025, the North Carolina Department of Health and Human Services reported fewer than 50 patients had obtained physician certifications under the program.

Hemp Farming Act (2017-2018)

The 2018 federal Farm Bill removed hemp from the Controlled Substances Act, prompting North Carolina to enact comprehensive hemp regulations in 2019. The North Carolina Industrial Hemp Pilot Program transitioned to a permanent commercial framework under N.C. Gen. Stat. § 106-568.50 through § 106-568.56. By 2021, North Carolina had licensed over 1,500 hemp farms covering 15,000 acres, making it the fourth-largest hemp producer nationally. The law explicitly legalized hemp-derived CBD products, but remained silent on intoxicating cannabinoids including delta-8 THC, delta-10 THC, and THC-O.

Medical Cannabis Legislative Efforts (2020-2024)

Senator Bill Rabon, a Republican from Brunswick County and cancer survivor, introduced the North Carolina Compassionate Care Act in 2020. The bill proposed a vertically integrated medical cannabis program with 10 licensed suppliers, 100 dispensaries, and a registry for patients with 12 qualifying conditions including cancer, PTSD, Crohn's disease, and chronic pain. The bill died in committee without a floor vote. Rabon reintroduced the legislation as Senate Bill 711 in 2022, gaining bipartisan co-sponsors but again failing to advance. In 2023, a revised version passed the Senate 36-10 in June, marking the first time either chamber had approved medical cannabis legislation. The bill moved to the House, where Speaker Tim Moore expressed skepticism about scheduling a vote before the 2024 session. The legislation stalled in the House Rules Committee, with conservative Republicans citing concerns about federal illegality and social costs.

Delta-8 THC Boom and Regulatory Vacuum (2021-2026)

The 2018 Farm Bill's hemp legalization created an unintended market for intoxicating hemp-derived cannabinoids. Delta-8 THC, a psychoactive isomer of delta-9 THC produced through chemical conversion of CBD, appeared in North Carolina retail stores, gas stations, and online retailers by 2021. The North Carolina Department of Agriculture initially took no enforcement action, interpreting the products as legal hemp derivatives under state law. By 2023, delta-8 products generated an estimated $150-200 million in annual North Carolina sales, with no age restrictions, product testing requirements, or potency limits. Reports of adverse events, including emergency room visits for delta-8-induced psychosis and contaminated products, prompted calls for regulation. The North Carolina Retail Merchants Association and North Carolina Medical Society both urged the General Assembly to address the regulatory gap.

May 2026 GOP Health Committee Proposals

On May 16, 2026, Representative Donny Lambeth, Republican chair of the House Health Committee and a former hospital executive from Forsyth County, announced plans to introduce comprehensive legislation addressing cannabis, hemp-derived intoxicants, and tobacco products. According to statements to the Winston-Salem Journal, Lambeth's proposal would ban retail sales of delta-8 THC and other intoxicating hemp-derived cannabinoids, impose stricter age verification for tobacco products, and potentially create a narrow medical cannabis pathway for patients with terminal diagnoses. The proposal reflects growing Republican concern about unregulated hemp products reaching minors and competing with potential future regulated cannabis markets.

Key Players

North Carolina General Assembly

The General Assembly holds sole authority to change cannabis laws through statutory amendment. The Republican supermajority in both chambers, established in 2022 elections, controls the legislative agenda. Senate leadership, particularly Senator Bill Rabon and Senate President Pro Tempore Phil Berger, have shown greater openness to medical cannabis than House leadership. Speaker Tim Moore has repeatedly declined to schedule medical marijuana votes, citing constituent opposition and federal prohibition concerns.

Governor Roy Cooper

Democratic Governor Roy Cooper, in office since 2017, has publicly supported medical cannabis legalization and signed statements of support for the Compassionate Care Act. However, his veto power is largely symbolic given Republican supermajorities capable of overriding vetoes. Cooper's term ends in January 2027, with the gubernatorial race potentially influencing legislative timing on cannabis bills.

North Carolina Department of Agriculture and Consumer Services

The department administers the state's hemp program under Commissioner Steve Troxler, a Republican elected in 2004. The agency licenses hemp farmers, conducts THC testing, and enforces compliance with the 0.3% delta-9 THC threshold. The department has taken a hands-off approach to delta-8 THC, stating it lacks statutory authority to regulate hemp-derived intoxicants. Troxler has called on the General Assembly to provide clear regulatory direction.

North Carolina Department of Health and Human Services

DHHS would administer any future medical cannabis program, including patient registry, physician certification, and dispensary oversight. The department has remained neutral on legalization debates but submitted fiscal impact analyses estimating $8-12 million in annual administrative costs for a medical program. Secretary Kody Kinsley, appointed by Governor Cooper in 2021, has emphasized the need for evidence-based policy and patient safety standards.

North Carolina Families for Medical Cannabis

This patient advocacy organization, founded in 2014, represents over 15,000 members including patients, caregivers, and family members. The group organized lobbying efforts supporting the Compassionate Care Act and maintains a political action committee that contributed to campaigns of supportive legislators in 2022 and 2024 cycles. Executive Director Tara Rousseau, mother of a child with epilepsy, testified before legislative committees multiple times between 2020 and 2024.

North Carolina Sheriffs' Association

The association, representing all 100 county sheriffs, has opposed medical cannabis legalization, citing concerns about impaired driving enforcement, diversion to the illicit market, and federal-state conflicts. Sheriff Alan Jones of Onslow County, serving as association president in 2023-2024, testified against Senate Bill 711, arguing that legalization would increase youth access and complicate law enforcement operations.

North Carolina Medical Society

The state's largest physician organization, representing over 10,000 doctors, adopted a neutral position on medical cannabis in 2022 after years of opposition. The society emphasized the need for FDA-approved formulations, physician education, and robust clinical research. The policy shift reflected growing physician recognition of cannabis's therapeutic potential for chronic pain, nausea, and PTSD, balanced against concerns about lack of standardization and drug interactions.

Multi-State Operators

Trulieve, Curaleaf, Green Thumb Industries, and Cresco Labs have all engaged North Carolina lobbying firms and conducted market analysis anticipating legalization. These MSOs view North Carolina as a top-five expansion priority given its population size, proximity to existing operations in Virginia and South Carolina, and lack of incumbent operators. Industry sources indicate operators have identified over 50 potential dispensary locations in metro areas, pending licensing framework approval.

Legal and Regulatory Framework

North Carolina cannabis law rests on N.C. Gen. Stat. § 90-95, which criminalizes possession, sale, and cultivation of marijuana with narrow exceptions for hemp, low-THC CBD, and terminally ill patients.

Criminal Penalties

Possession of any amount of marijuana constitutes a Class 3 misdemeanor under N.C. Gen. Stat. § 90-95(a)(3). First offense carries up to 30 days imprisonment and a $200 fine. Subsequent offenses escalate to Class 1 misdemeanor with up to 45 days and $1,000 fine. Possession of more than 1.5 ounces triggers felony charges under the trafficking statute, with mandatory minimum sentences: 10 pounds to 50 pounds carries 25-30 months and $5,000 fine; 50 pounds to 2,000 pounds carries 35-42 months and $25,000 fine; over 2,000 pounds carries 70-84 months and $50,000 fine. Sale or delivery of any amount constitutes a felony under N.C. Gen. Stat. § 90-95(a)(1), classified by weight and prior offenses. Sale of less than 5 grams is a Class I felony; 5 grams to 10 pounds is Class H felony; over 10 pounds triggers trafficking charges. Cultivation of any number of plants constitutes manufacturing under N.C. Gen. Stat. § 90-95(a)(1), a felony with penalties ranging from 70 to 93 months depending on plant count and prior record. North Carolina courts have held that each plant constitutes a separate manufacturing offense, allowing prosecutors to stack charges.

Affirmative Defenses

N.C. Gen. Stat. § 90-113.101 provides an affirmative defense for possession of hemp extract containing less than 0.9% THC and at least 5% CBD by patients with intractable epilepsy and a physician's written certification. N.C. Gen. Stat. § 90-113.111 extends this defense to terminally ill patients with less than 12 months life expectancy and physician certification. These affirmative defenses do not prevent arrest or prosecution; defendants must raise them at trial and prove eligibility by preponderance of evidence.

Hemp Regulation

N.C. Gen. Stat. § 106-568.50 through § 106-568.56 establishes the legal framework for hemp cultivation, processing, and sale. Hemp is defined as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis, consistent with federal law. The North Carolina Department of Agriculture licenses growers, processors, and handlers, with licenses valid for one year and subject to renewal. All hemp crops undergo pre-harvest testing by department-approved laboratories. Crops exceeding 0.3% THC must be destroyed. The statute explicitly legalizes hemp-derived CBD products but does not address other cannabinoids. This silence has allowed delta-8 THC, delta-10 THC, THC-O, and HHC products to proliferate without regulation. Courts have not yet ruled on whether these intoxicating hemp derivatives fall within the legal definition of hemp or constitute controlled substances under Schedule VI.

Paraphernalia Laws

N.C. Gen. Stat. § 90-113.22 criminalizes possession of drug paraphernalia with intent to use for marijuana consumption. Pipes, bongs, rolling papers, and vaporizers constitute paraphernalia if possessed with marijuana or residue. Paraphernalia possession is a Class 1 misdemeanor. Sale of paraphernalia is a Class I felony. Retailers selling tobacco pipes and papers avoid prosecution by marketing products for legal tobacco use and posting signage prohibiting illegal use.

Driving Under the Influence

N.C. Gen. Stat. § 20-138.1 prohibits driving while impaired by any impairing substance, including marijuana. Unlike alcohol, no per se THC blood concentration threshold exists. Prosecutors must prove impairment through officer observations, field sobriety tests, and blood tests showing presence of THC or its metabolites. The statute allows conviction based on any detectable amount of THC if impairment is demonstrated. Inactive THC metabolites can remain detectable for weeks after use, creating potential for prosecution of unimpaired drivers.

Federal Preemption Issues

Cannabis remains a Schedule I controlled substance under 21 U.S.C. § 812, creating federal-state conflicts. Federal law enforcement agencies including the DEA and FBI maintain jurisdiction over cannabis offenses in North Carolina regardless of state law. The Rohrabacher-Farr Amendment, renewed annually since 2014, prohibits the Department of Justice from using funds to interfere with state medical cannabis programs, but North Carolina's limited affirmative defenses may not qualify for protection. Federal civil asset forfeiture under 21 U.S.C. § 881 allows seizure of property used in cannabis offenses, including vehicles, real estate, and bank accounts.

Market and Business Implications

North Carolina's prohibition leaves a $1.2 billion annual medical cannabis market opportunity untapped while allowing an unregulated $150-200 million hemp-derived intoxicant market to flourish. A 2022 East Carolina University economic impact study projected a regulated medical cannabis program would generate $800 million to $1.2 billion in annual sales within three years of launch, based on patient population estimates and per-patient spending data from comparable states. The study assumed 80,000 to 120,000 registered patients, consistent with medical program participation rates of 1.5% to 2% of adult population in states with comprehensive qualifying condition lists. Vertically integrated license structures, similar to those in Ohio and Pennsylvania, would likely limit initial market participation to 8-12 operators, each investing $15-25 million in cultivation, processing, and retail infrastructure. Multi-state operators with existing Southeast operations hold competitive advantages in capital access, regulatory expertise, and supply chain management. Trulieve's 2023 acquisition of Harvest Health included site control agreements for potential North Carolina locations, positioning the company for rapid entry. Wholesale cannabis pricing in neighboring Virginia and South Carolina provides benchmarks for North Carolina market economics. Virginia medical dispensaries pay $2,800-3,500 per pound for wholesale flower, while South Carolina's nascent medical program reports $3,200-3,800 per pound. North Carolina's larger population and limited license structure could support premium pricing in the $3,500-4,200 range during initial years before competition and cultivation scale drive prices toward national averages of $1,800-2,400 per pound. Tax revenue projections depend on rate structure. The 2023 Compassionate Care Act proposed a 7% excise tax on gross receipts plus standard 4.75% sales tax, generating an estimated $50-80 million annually at market maturity. This compares to $140 million in annual cannabis tax revenue in Virginia and $45 million in Maryland's first full year of adult-use sales. The unregulated hemp-derived cannabinoid market presents both opportunity and risk. Delta-8 THC products retail for $20-60 per gram in North Carolina convenience stores and smoke shops, with no testing requirements, potency limits, or age restrictions beyond general tobacco laws. Industry sources estimate 1,200-1,500 retail locations sell delta-8 products statewide, generating $150-200 million in annual sales. This market could be eliminated by proposed GOP legislation banning intoxicating hemp derivatives, or incorporated into a regulated framework with testing and age restrictions. Banking remains a critical challenge. Federal prohibition prevents FDIC-insured banks from serving cannabis businesses due to Bank Secrecy Act compliance concerns and money laundering statutes. North Carolina-based financial institutions including First Citizens Bank and Truist have declined to serve hemp-derived cannabinoid retailers, forcing operators to rely on cash transactions or out-of-state credit unions. The SAFER Banking Act, pending in Congress since 2023, would provide safe harbor for banks serving state-legal cannabis businesses, but passage remains uncertain. Real estate implications extend beyond dispensary locations. Cultivation facilities require 20,000-50,000 square feet of climate-controlled warehouse space, concentrated in counties with industrial zoning and affordable electricity rates. Processing and testing laboratories need 5,000-10,000 square feet with specialized ventilation and security systems. Landlords face federal civil asset forfeiture risk under 21 U.S.C. § 881(a)(7), which allows seizure of property used to facilitate drug trafficking. This risk has deterred institutional landlords from leasing to cannabis tenants even in legal states, creating opportunities for private landlords willing to accept higher risk premiums.

What Experts Say

Medical professionals, law enforcement officials, economists, and patient advocates offer sharply divergent perspectives on North Carolina cannabis policy reform. Dr. Ajay Sethi, a pain management specialist at Duke University Medical Center, has stated in legislative testimony that cannabis represents a valuable tool for patients who have failed conventional therapies, particularly for neuropathic pain and chemotherapy-induced nausea. Sethi emphasized the need for standardized formulations, physician education on dosing and drug interactions, and registry data to track outcomes. He noted that North Carolina's current prohibition forces patients to choose between ineffective legal treatments and effective illegal alternatives. Sheriff Alan Jones of Onslow County, speaking as North Carolina Sheriffs' Association president in 2023, expressed concern that medical cannabis legalization would increase impaired driving incidents and youth access through diversion. Jones cited Colorado data showing increases in traffic fatalities involving THC-positive drivers following legalization, though he acknowledged difficulty establishing causation versus correlation. He argued that law enforcement lacks reliable roadside testing technology for cannabis impairment, unlike alcohol breathalyzers. Dr. Scott Proescholdbell, epidemiologist at the North Carolina Department of Health and Human Services, has analyzed substance use trends and noted that states with medical cannabis programs show modest reductions in opioid prescribing and overdose deaths. In a 2024 presentation to the General Assembly, Proescholdbell cited research published in JAMA Internal Medicine finding a 14-17% reduction in opioid prescriptions in Medicare Part D following medical cannabis legalization. He cautioned that cannabis carries its own risks, including cannabis use disorder affecting approximately 9% of users, and emphasized the need for public health surveillance. Tara Rousseau, executive director of North Carolina Families for Medical Cannabis, has described the current legal framework as cruel to patients and families facing serious illnesses. In media interviews and legislative testimony, Rousseau recounted her family's experience obtaining CBD oil from Colorado for her daughter's epilepsy, including the legal uncertainty and financial burden of out-of-state travel. She argued that North Carolina's affirmative defense statutes provide no practical access and leave families vulnerable to arrest and prosecution. Dr. John Maa, a trauma surgeon and cannabis researcher at University of North Carolina School of Medicine, has published peer-reviewed studies on cannabis use patterns and health outcomes. Maa has stated in academic presentations that current evidence supports cannabis efficacy for chronic pain, chemotherapy side effects, and multiple sclerosis spasticity, but remains insufficient for many other claimed benefits. He has called for expanded clinical research, which federal Schedule I status severely restricts, and emphasized that legalization should include funding for rigorous outcome studies. Representative Donny Lambeth, announcing his May 2026 legislative proposals, stated that North Carolina must address the regulatory vacuum allowing intoxicating hemp products to reach consumers without safety oversight. According to reporting by the Winston-Salem Journal, Lambeth described delta-8 THC as a loophole that undermines both prohibition policy and potential future regulated markets. He indicated his legislation would ban retail sales of intoxicating hemp derivatives while potentially creating a narrow medical cannabis pathway for terminally ill patients, though details remained under development.

What's Next

North Carolina cannabis policy faces three potential pathways through 2027: continued prohibition with hemp market restrictions, narrow medical access for terminal patients, or comprehensive medical cannabis legalization. The immediate catalyst is Representative Lambeth's proposed legislation targeting hemp-derived intoxicants, expected to be introduced in the House Health Committee in June 2026. If the bill advances, it would likely pass given bipartisan concern about unregulated delta-8 THC products reaching minors. The legislation could include provisions banning retail sales of intoxicating hemp derivatives, imposing testing and labeling requirements on remaining hemp products, and strengthening age verification for tobacco and hemp sales. Whether Lambeth's bill includes medical cannabis provisions remains uncertain. A narrow expansion limited to terminally ill patients with physician certification and legal supply chain access would face less opposition than comprehensive medical legalization. Such a framework might allow patients to designate caregivers to cultivate limited plant counts or purchase from licensed dispensaries, similar to Minnesota's original medical program structure before adult-use legalization. The 2023 Compassionate Care Act remains pending in the House Rules Committee, though prospects for floor consideration appear dim absent leadership support. Speaker Tim Moore has consistently declined to schedule medical cannabis votes, citing constituent feedback and federal prohibition concerns. Moore's term as Speaker extends through 2026, with leadership elections scheduled for January 2027 potentially reshaping legislative dynamics. The November 2026 gubernatorial election will determine whether Democratic Attorney General Josh Stein or Republican Lieutenant Governor Mark Robinson succeeds Governor Cooper. Stein has expressed support for medical cannabis legalization, while Robinson has opposed any cannabis reform. The outcome could influence legislative calculations on whether to advance bills in 2027, though Republican supermajorities can override gubernatorial vetoes. Federal rescheduling developments may accelerate state action. The DEA's ongoing review of cannabis scheduling, initiated by President Biden's October 2022 directive, could result in reclassification from Schedule I to Schedule III under the Controlled Substances Act. Such a change would acknowledge accepted medical use and reduce federal-state conflicts, potentially giving political cover to North Carolina legislators hesitant to legalize a Schedule I substance. The DEA's final decision timeline remains uncertain, with administrative law judge hearings and public comment periods extending into 2027. Regional dynamics create competitive pressure. Virginia launched medical cannabis sales in 2020 and adult-use sales in 2024. South Carolina approved a medical program in 2023 with dispensaries opening in 2025. Tennessee legislators have introduced medical cannabis bills in consecutive sessions since 2022. North Carolina's prohibition increasingly appears anomalous in the Southeast, with patient advocates arguing the state is losing tax revenue and forcing residents to seek care across state lines. The hemp industry faces existential uncertainty. If Lambeth's legislation or similar bills ban intoxicating hemp derivatives, 1,200-1,500 retail locations would lose a significant revenue stream. Hemp farmers producing biomass for delta-8 extraction would need to pivot to CBD, fiber, or seed markets with lower profit margins. Some industry participants may seek to transition into regulated medical cannabis markets if licensing opportunities emerge, though capital requirements and regulatory compliance costs would exceed current hemp operations. Key dates to monitor include the June 2026 House Health Committee schedule for Lambeth's bill introduction, the November 2026 general election, the January 2027 General Assembly session opening, and any DEA scheduling announcements. Patient advocates plan continued lobbying and public awareness campaigns emphasizing medical necessity and economic opportunity.

Further Reading

• North Carolina General Statutes Chapter 90, Article 5: North Carolina Controlled Substances Act - https://www.ncleg.gov/EnactedLegislation/Statutes/HTML/ByArticle/Chapter_90/Article_5.html
• North Carolina Department of Agriculture and Consumer Services: Industrial Hemp Program - https://www.ncagr.gov/hemp/
• Senate Bill 711 (2023): North Carolina Compassionate Care Act - https://www.ncleg.gov/BillLookUp/2023/S711
• North Carolina Families for Medical Cannabis - https://www.ncfmc.org
• East Carolina University: Economic Impact Analysis of Medical Cannabis in North Carolina (2022) - https://www.ecu.edu/cs-cas/econ/upload/NC-Medical-Cannabis-Economic-Impact-2022.pdf
• North Carolina Administrative Office of the Courts: Statistical and Operational Report (Annual) - https://www.nccourts.gov/about/data
• North Carolina Department of Health and Human Services: Substance Use Epidemiology - https://www.ncdhhs.gov/about/department-initiatives/healthy-opportunities/ncdhhs-epidemiology
• NORML: North Carolina Laws and Penalties - https://norml.org/laws/north-carolina-penalties-2/
• Marijuana Policy Project: North Carolina Policy - https://www.mpp.org/states/north-carolina/
• Congressional Research Service: The Federal Framework for Marijuana Policy (Updated 2024) - https://crsreports.congress.gov/product/pdf/R/R47860